While Bristol’s highly anticipated TYK2 inhibitor BMS-986165 is being studied in Phase III psoriasis clinical trials, all five of the company’s near- and mid-term launches come from Celgene’s pipeline:

A US FDA approval decision is expected in March for the S1P receptor modulator ozanimod in multiple sclerosis.
The FDA may decided on a second indication for erythroid maturation agent Reblozyl (luspatercept) in anemia associated with very low to intermediate risk myelodysplastic syndromes (MDS). It was approved for transfusion-dependent beta-thalassemia in November. (Also see "Keeping Track: Biosimilars, Novel Approvals, And Ebola" - Pink Sheet, 11 November, 2019.)
FDA approval for the CD19-targeting chimeric antigen receptor T-cell (CAR-T) therapy lisocabtagene maraleucel (JCAR017, liso-cel) for adults with relapsed or refractory B-cell lymphoma is expected later this year after a BLA filing in December. (Also see "Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings" - Scrip, 10 December, 2019.)
A BLA filing is expected in the first half of 2020 for the B-cell maturation antigen (BCMA)-targeting CAR-T idecabtagene vicleucel (ide-cel, bb2121) in relapsed or refractory multiple myeloma, setting the stage for FDA approval later in the year or early in 2021.
A submission to the FDA is being prepared for CC-486, an oral version of Celgene’s hypomethylating agent Vidaza (azacitidine), as maintenance therapy after chemotherapy for acute myeloid leukemia (AML) patients who are ineligible for hematopoietic stem cell transplants.

BMS Earnings Beat Estimates, But Opdivo Sales Slide Continues

More from Earnings

More from Business